Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is …
Full KNSA analysis →
Competitive advantage assessment
Key strengths
Strong Interest Coverage & Conservative LeverageDebt serviceability is strong (score 0.85), with robust interest coverage.
Consistent Cash GenerationCash generation is strong and consistent (score 0.81).
Key risks
Revenue Volatility Signals Weak StickinessRevenue volatility is high (stability score 0.16), suggesting weak customer stickiness.
Volatile Margins Suggest CyclicalityMargin volatility is high (stability score 0.21), suggesting cyclical exposure or competitive pressure.
The dashed ring is the peer median. Defense scores are percentile ranks
against peers, so 50 is roughly the typical company in this group.
Upgrade to unlock the signals and evidence behind each defense.
Premium access
Unlock full defense analysis
Get key signals, strengths, and risks for every moat dimension.
Where KNSA ranks in Drug Manufacturers - Specialty & Generic
Kiniksa Pharmaceuticals, Ltd. ranks #21 of 91
scored companies in Drug Manufacturers - Specialty & Generic by moat score — the top 23%.
The widest moat in the group is Zoetis Inc. (ZTS)
at 85/100.
Moat scores for companies ranked near KNSA in Drug Manufacturers - Specialty & Generic
Pricing power is the ability to raise prices without losing volume.
Cost Advantage
Score 74
· 15% of the moat score
A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.
Customer Stickiness
Score 55
· 15% of the moat score
Stickiness is what makes revenue repeat without being re-won every year.
Capital Efficiency
Score 72
· 18% of the moat score
Capital efficiency asks what the company earns on the money tied up in the business.
Resilience
Score 82
· 17% of the moat score
Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.
Scale & Market Position
Score 70
· 15% of the moat score
Scale matters only when it converts into economics.
What is Kiniksa Pharmaceuticals, Ltd.'s moat score?
Kiniksa Pharmaceuticals, Ltd. (KNSA) scores 65 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as moderate. It ranks #21 of 91 scored companies in Drug Manufacturers - Specialty & Generic, the top 23%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 90 companies in Drug Manufacturers - Specialty & Generic. Its strongest defense is Resilience (82/100) and its weakest is Pricing Power (44/100).
How does Kiniksa Pharmaceuticals, Ltd. compare with other Drug Manufacturers - Specialty & Generic companies?
Kiniksa Pharmaceuticals, Ltd. ranks #21 of 91 scored companies in Drug Manufacturers - Specialty & Generic by moat score. The widest moat in Drug Manufacturers - Specialty & Generic is Zoetis Inc. (ZTS) at 85/100. The companies ranked closest are Emergent BioSolutions Inc. (EBS) at 66 just above it and Teva Pharmaceutical Industries (TEVA) at 64 just below it.
How is the moat score calculated?
Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 90 companies in Drug Manufacturers - Specialty & Generic. The defenses are then weighted to produce the overall score out of 100.
Why is Kiniksa Pharmaceuticals, Ltd. scored with the Corporate Default template?
Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.
Which competitive defenses are measured for Kiniksa Pharmaceuticals, Ltd.?
The Corporate Default template measures 6 defenses, and KNSA scores: Pricing Power (44), Cost Advantage (74), Customer Stickiness (55), Capital Efficiency (72), Resilience (82), Scale & Market Position (70). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.
We value your privacy
We use cookies to enhance your browsing experience, analyze site traffic, and personalize content. By clicking 'Accept All', you consent to our use of cookies.
Read our cookie policy
Cookie Preferences
Manage your cookie preferences. Essential cookies are always enabled.